Agilent Technologies Inc (A)vsMyriad Genetics Inc (MYGN)
A
Agilent Technologies Inc
$112.98
-1.07%
HEALTHCARE · Cap: $31.96B
MYGN
Myriad Genetics Inc
$4.68
+1.52%
HEALTHCARE · Cap: $435.75M
Smart Verdict
WallStSmart Research — data-driven comparison
Agilent Technologies Inc generates 757% more annual revenue ($7.07B vs $824.50M). A leads profitability with a 18.3% profit margin vs -44.4%. A appears more attractively valued with a PEG of 1.19. A earns a higher WallStSmart Score of 61/100 (C+).
A
Buy61
out of 100
Grade: C+
MYGN
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-318.5%
Fair Value
$30.80
Current Price
$112.98
$82.18 premium
Intrinsic value data unavailable for MYGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 20 in profit
Strong operational efficiency at 22.9%
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Weak financial health signals
Earnings declined 3.6%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -68.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : A
The strongest argument for A centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 22.9%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : MYGN
The strongest argument for MYGN centers on Price/Book. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bear Case : A
The primary concerns for A are Altman Z-Score, Piotroski F-Score, EPS Growth.
Bear Case : MYGN
The primary concerns for MYGN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
A profiles as a mature stock while MYGN is a turnaround play — different risk/reward profiles.
MYGN carries more volatility with a beta of 1.93 — expect wider price swings.
A is growing revenue faster at 7.0% — sustainability is the question.
A generates stronger free cash flow (175M), providing more financial flexibility.
Bottom Line
A scores higher overall (61/100 vs 44/100), backed by strong 18.3% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agilent Technologies Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.
Myriad Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?